Get the latest news alerts: at Twitter.

Local Tech Wire

RALEIGH, N.C. – Representatives of (Nasdaq: BDSI) will meet with the U.S. Food and Drug Administration to discuss the firm’s proposed anti-nausea product.

The meeting is set for March 17.

BDSI wants to launch Phase I clinical trials of its anti-nausea and vomiting product in the second quarter. The product is designed to deliver drugs through a dissolvable film, thus enabling drug delivery through the inner lining of the cheek.

BDSI believes the product, called BEMA Granisestron, would help patients who have problems taking drugs orally.

“Patients experiencing nausea and vomiting often have difficulty taking oral medications. Additionally, absorption of drug from the gastrointestinal tract can be highly variable in these individuals,” said Andrew Finn, executive vice president of product development at BDSI. “Having a formulation of an antiemetic [anti-nausea, vomiting] that does not require swallowing and gastric absorption could possibly lead to faster and more consistent blood levels of drug. We believe that such a product could have significant potential.”

BEMA refers to BioDelivery’s BioErodible MucoAdhesive technology. It would be used to deliver the antiemetic drug Granisetron, or Kytril, that is sold by Genetich.

The FDA has already approved use of BEMA to deliver a breakthrough pain opioid treatment. BDSI also is in Phase II testing of a BEMA-delivered treatment for acute and chronic pain.